Background: In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS) in the overall study population of patients with advanced non-small-cell lung cancer (NSCLC).
introduction Standard, first-line platinum-doublet chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) is usually withdrawn following four to six cycles, due to cumulative toxicity and a lack of increased efficacy with prolonged chemotherapy administration [1] . This leads to a break in therapeutic pressure on the tumour, until second-line therapy is initiated at the time of disease progression.
The oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) erlotinib is an established option for second-line treatment of patients with advanced NSCLC [1] [2] [3] . Treatment with erlotinib produces significant survival benefits in a broad patient population and delays the time to the deterioration of key disease symptoms (cough, dyspnoea, and pain), without having a negative impact on patients' quality of life (QoL) [2, 4] . These benefits are particularly important, given that survival outcomes with erlotinib are similar to those with the approved second-line cytotoxic chemotherapy options docetaxel and pemetrexed [5, 6] .
Until recently, treatment guidelines recommended waiting until disease progression before administering later-line systemic anticancer treatments [1, 3] . However, this treatment break meant that a substantial proportion (30%-50%) of patients did not receive any further treatment, often because of rapid disease progression and/or rapid worsening of performance status after the completion of first-line treatment [7] [8] [9] .
The introduction of maintenance therapy represents a paradigm shift in the treatment of advanced NSCLC and is intended to delay disease progression and extend survival, without adversely affecting patients' QoL. This approach involves the administration of an active treatment immediately after first-line chemotherapy, thus maintaining the clinical benefit obtained. Maintenance therapy regimens may include the continuation, until disease progression or unacceptable toxicity, of a non-platinum component of first-line therapy, such as gemcitabine or bevacizumab [10] [11] [12] . Alternatively, maintenance therapy can involve a 'switch' to a new agent, as exemplified by recent trials with erlotinib and pemetrexed [7, 10, 13, 14] . Maintenance therapy with erlotinib or pemetrexed may also be termed 'early second-line therapy' since this involves the earlier introduction of approved second-line agents [14] .
In the phase III SequentiAl Tarceva Ò in UnResectable NSCLC (SATURN; BO18192) study, maintenance therapy with erlotinib significantly increased progression-free and overall survival (PFS and OS) versus placebo in both the overall intention-to-treat (ITT) population and in patients with EGFR immunohistochemistry (IHC)-positive tumours [13] . These benefits were observed across clinical and molecular biomarker subgroups, with no impairment in QoL.
Although the benefits of maintenance therapy in NSCLC have now been established, it is likely that some patients may derive greater benefits from this approach than others. Approximately, 70%-80% of patients obtain some clinical benefit from standard, first-line platinum-doublet chemotherapy regimens, with 40%-50% achieving stable disease (SD) as their best response [8, 9, [15] [16] [17] [18] . Compared with patients achieving complete or partial tumour response (CR or PR), those with SD after first-line chemotherapy may have substantial residual tumour burden, continuing symptoms, and a worse prognosis [19, 20] . These patients may, therefore, be particularly suitable candidates for maintenance therapy.
We report a prospectively planned analysis of the SATURN study, to evaluate the clinical benefit obtained with maintenance erlotinib, according to response to first-line chemotherapy.
methods
The study design, key inclusion/exclusion criteria, biomarker analyses, assessments, and statistical analysis have been reported separately [13, 21] , and are, therefore, only summarised here.
study design and patients
Patients with advanced (stage IIIB/IV) NSCLC, whose disease did not progress following four cycles of standard platinum-doublet chemotherapy, and who had a performance status of zero or one, were randomised (1 : 1) to receive maintenance therapy with either erlotinib 150 mg/day or placebo until unacceptable toxicity or disease progression (PD). The co-primary end points were PFS in the ITT population and PFS in the subpopulation of patients with EGFR protein expression (as assessed by IHC), where at least 10% of tumour cells had membrane staining (IHC-positive). OS was a secondary end point.
The study complied with the Declaration of Helsinki and Good Clinical Practice guidelines, and the protocol was approved at all participating centres by respective ethics committees. All patients provided written informed consent to participate in the study, for collection of tumour samples, and for EGFR IHC testing. Consent for additional molecular analyses was collected separately.
EGFR mutation analyses
Mandatory tumour samples were collected before initiating first-line chemotherapy. Exons 18-21 of the EGFR gene were subjected to PCR assay using nested primers, with mutations confirmed on both strands of at least two PCR products. Samples were classified as activating EGFR mutation positive if the most commonly observed activating mutations were detected (deletions in the region around E746-A750 of exon 19 and/or the L858R point mutation in exon 21) [22] .
assessments
Baseline characteristics were assessed at the time of randomisation and included smoking status (never smokers [patients who had smoked <100 cigarettes in their lifetime], former smokers [those who had smoked ‡100 cigarettes but had not smoked within the last year], and current smokers [all remaining patients]). Tumour tissue was collected from all patients at study screening, and tumour assessments were carried out after completion of chemotherapy, then 6-weekly until week 48, and every 12 weeks thereafter or until disease progression. Tumour response was classified by RECIST version 1.0. Adverse events (AEs) were classified according to the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) version 3.0, and QoL was evaluated by use of the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire. The Trial Outcome Index (TOI) was defined as the sum of the scores of the physical well being, functional well being , and lung cancer subscale of the FACT-L instrument.
statistical analyses
Time-to-event data were measured from the time of randomisation. Survival outcomes were assessed by use of Kaplan-Meier curves, and hazard ratios (HRs) and 95% confidence intervals (CIs) were determined by Cox regression model. Basic comparisons between the erlotinib and placebo groups were carried out using a two-sided log-rank test. Cox regression analysis of OS was carried out in the ITT population, including response to first-line chemotherapy (CR/PR versus SD) and other baseline characteristics, with stratification factors as covariates. A multiple Cox regression with stepwise selection was also carried out for the ITT population.
results
A total of 1949 patients were screened and received first-line platinum-based doublet chemotherapy. Of the 889 non-PD patients who were subsequently randomised to the ITT population (438 to erlotinib and 451 to placebo), 487 patients (55%) had SD after first-line chemotherapy, 394 patients (44%) had CR/PR, 5 (<1%) patients progressed before randomisation, and the response status of 3 patients (<1%) was unknown. The remaining patients were not randomised to the study due to PD (22%), ineligibility for randomisation (20%), death (8%), and withdrawn consent (5%) (see Cappuzzo et al. [13] for further details of reasons for ineligibility). In the ITT population, baseline clinical and biomarker characteristics were well balanced between the SD and CR/PR groups and also between the treatment arms within these groups (Table 1) . Post-study therapy was documented in approximately two-thirds of patients (in each treatment arm and response (14) 29 (14) 34 (13) original articles Annals of Oncology to chemotherapy subgroup) and was also generally well balanced ( Table 2) . Analysis of PFS according to response to first-line chemotherapy showed similar and significant benefits with maintenance erlotinib, compared with placebo, for both the SD and CR/PR groups ( Figure 1A and 1B) . The HR for erlotinib benefit was 0.68 in the SD group (95% CI 0.56-0.83; P < 0.0001) with a median PFS of 12.1 versus 11.3 weeks (2.8 versus 2.6 months), respectively. The HR in the CR/PR group was 0.74 (0.60-0.92; P = 0.0059) with a median PFS of 12.4 versus 11.1 weeks (2.9 versus 2.6 months), respectively.
In order to assess the prognostic impact of tumour response after first-line chemotherapy, a multiple Cox regression model of OS was carried out, including baseline characteristics and stratification factors as covariates. SD after first-line chemotherapy was a significant negative prognostic factor. For the comparison of CR/PR versus SD, which included baseline characteristics and stratification factors, the HR was 0.79 (95% CI 0.67-0.93; P = 0.005).
In the SD group, OS was significantly prolonged with maintenance erlotinib, compared with placebo (HR = 0.72 [95% CI 0.59-0.89]; P = 0.0019; median OS 11.9 versus 9.6 months, respectively) ( Figure 1C ). No significant difference in OS was observed in the CR/PR group (HR = 0.94 [95% CI 0.74-1.20]; P = 0.6181; median OS 12.5 versus 12.0 months in the erlotinib and placebo groups, respectively) ( Figure 1D ). The OS benefit with erlotinib in the SD group remained significant in a multiple Cox regression analysis including all factors in the model (HR = 0.71 [95% CI 0.58-0.88]; P = 0.0019).
In the SD group, the 1-year event-free rates for PFS were 5.2% and 1.7% for maintenance erlotinib and placebo, respectively. In the CR/PR group, the corresponding rates were 41 (22) 31 (15) 45 (18) 49 (21) Vinorelbine, n (%)
15 (8) 22 (10) 17 (7) 20 (9) Erlotinib, n (%)
15 (8) 33 (16) 18 (7) 35 (15) Gefitinib, n (%)
3 (2) 13 (6) 6 (2) 13 (6) CR, complete response; PR, partial response; SD, stable disease. 7.6% and 3.8%, respectively. For OS, the 1-year event-free rates were 46.8% and 40.9% for maintenance erlotinib and placebo, respectively, in the SD group, and 46.2% and 47.1%, respectively, in the CR/PR group. (Figure 3 ). In patients whose tumours had activating EGFR mutations (n = 30), OS was also improved with erlotinib (HR = 0.48), although the 95% CIs were wide (0.14-1.62) due to the small number of patients included in this analysis.
safety and QoL
The incidence of AEs was similar in the SD group to that observed in the overall population. Mild or moderate rash and diarrhoea were the most frequently observed erlotinibrelated toxic effects (Table 3) . QoL and symptom data in this analysis were also similar to the overall study population, with no erlotinib-related QoL impairment. In the SD group, the HRs were time to deterioration of QoL 0.97 (95% CI 0.75-1.26), time to symptom progression 0.92 (95% CI 0.70-1.22), and time to deterioration in the TOI 1.14 (95% CI 0.86-1.50).
Corresponding HRs in the CR/PR group were time to deterioration of QoL 0.93 (95% CI 0.69-1.24), time to symptom progression 0.92 (95% CI 0.67-1.26), and time to deterioration in the TOI 0.98 (95% CI 0.71-1.34).
discussion
In this pre-planned subgroup analysis of the SATURN study, PFS was significantly prolonged by maintenance erlotinib, Figure 2 . Subgroup analyses of overall survival among patients with stable disease (SD) after first-line chemotherapy. CI, confidence interval; EGFR; epidermal growth factor receptor; HR, hazard ratio; PS, performance status; WT, wild type. original articles Annals of Oncology regardless of the response to prior chemotherapy. A significant OS benefit was, however, only observed in patients who had SD after first-line chemotherapy (HR = 0.72; 2.3-month increase in median OS) compared with those who achieved CR/PR (HR = 0.94). These results were unlikely to have been influenced by underlying differences in the study subgroups, since all groups were well balanced with regard to baseline clinical and biomarker characteristics and post-study treatments. The differences observed in OS outcomes therefore result from the use of maintenance erlotinib and not from differences in prognostic factors or the use of subsequent therapy. This conclusion is supported by the multivariate analysis, in which the OS benefit in the SD group remained significant. Similar findings were reported in the phase III JMEN study of maintenance pemetrexed. The HR for OS in patients with non-squamous NSCLC having SD after first-line chemotherapy was substantially lower than in patients with CR/PR (0.61 versus 0.81, respectively) [23] .
In the overall SATURN population, patients whose tumours had activating EGFR mutations derived the greatest PFS benefit from maintenance erlotinib treatment (n = 49; HR = 0.10; P < 0.0001) [13] . However, the presence of these mutations was not required for benefit, as patients whose tumours did not have these mutations also obtained significant PFS and OS improvements (HR = 0.78 and 0.77, respectively) [13] . Similarly, the PFS and OS benefit in the SD group was not driven by the inclusion of patients whose tumours had activating EGFR mutations, as significantly improved PFS and OS was observed in the subgroup of patients whose tumours did not have these mutations (HR = 0.72 and 0.65 [3.7-month improvement in OS], respectively). This was further confirmed by a significant benefit in patients with tumours of squamous histology (HR for OS = 0.67; HR for PFS = 0.70), a group in which activating EGFR mutations are very rare [24] .
Patients with SD after first-line chemotherapy present a considerable challenge for physicians; such patients may have substantial residual disease. The SATURN study supports findings from other studies, which have shown that patients with SD after first-line chemotherapy have a worse prognosis than those with CR/PR [19, 20] . Patients with less tumour shrinkage following first-line chemotherapy are also less likely to receive subsequent therapy [25] . Collectively, these findings, and data from SATURN, suggest that a treatment break after first-line chemotherapy may not be appropriate in patients with SD. Such patients are more likely to progress rapidly, often with a rapid deterioration in performance status and so may be unable to receive second-line therapy. Maintenance therapy with oral erlotinib is therefore an attractive option in these patients, as it provides a significant and clinically meaningful OS benefit, is well tolerated, and does not negatively impact QoL.
Patients with SD after first-line chemotherapy are likely to have tumours that are at least partially resistant to cytotoxic therapy, and so they may benefit more from a change in therapeutic mechanism of action, compared with those who respond to chemotherapy. This is supported by preclinical findings showing an association between resistance to cytotoxic drugs and EGFR pathway activation [26, 27] , which may lead to increased sensitivity to EGFR inhibitors [27, 28] .
Significant and clinically meaningful PFS and OS benefits were observed with maintenance erlotinib in the ITT population of the SATURN study. In this pre-planned analysis, the OS benefit was significant only in patients who had SD after completing first-line chemotherapy: a group of patients who typically have a poor prognosis and who are less likely to be able to receive second-line treatment. Among the SD group, improved OS was observed across clinical subgroups, including in squamous and non-squamous histologies, and in patients whose tumours did not have activating EGFR mutations. Maintenance therapy with erlotinib may therefore be considered as a treatment option for patients with NSCLC and SD after first-line platinum-based doublet chemotherapy.
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